YPrime Earns Leader Status in Everest Group’s 2025 eCOA Assessment

YPrime has been recognized as a Leader in the Everest Group’s 2025 Life Sciences Electronic Clinical Outcome Assessment (eCOA) Products PEAK Matrix® Assessment. This acknowledgment highlights the company’s capability to manage complex clinical trials more efficiently, delivering high-quality data on a global scale.

The designation reflects YPrime’s commitment to advancing clinical trial technology. According to the Everest Group, the evaluation measures providers based on their vision, capability, and market impact. YPrime’s strong position in the Leader quadrant underscores its role as a trusted partner for major pharmaceutical companies, emerging biotechs, and contract research organizations (CROs). This recognition allows sponsors to launch studies more swiftly through flexible and reliable eCOA solutions.

“We’re proud to be named a Leader by Everest Group,” said Mike Hughes, Chief Product Officer at YPrime. “Our eCOA platform is built to meet the complexity and speed that today’s clinical trials demand—while simplifying processes and improving the experience for patients, sites, and sponsors alike. This recognition reinforces the value we’re delivering at scale.”

YPrime’s eCOA platform is designed to adapt to the pace and intricacies of modern clinical trials. The introduction of AI-powered localization tools has transformed the way sponsors approach global study startups. By automating and validating the translation migration process, YPrime enables quicker, more accurate deployments in over 250 languages across more than 100 countries. This innovation addresses long-standing industry challenges, facilitating faster multilingual study launches.

In addition to localization advancements, YPrime has also unveiled its Automated Data Change Form (DCF). This tool empowers site staff to make protocol-compliant data edits in minutes rather than days, significantly reducing a traditionally cumbersome and error-prone workflow in eCOA systems. The DCF enhances operational efficiency by streamlining approvals while maintaining comprehensive audit trails, thus improving both speed and data integrity at the site level.

YPrime continues to invest in connected device innovations. A recent integration with a glucometer eCOA was developed in close collaboration with diabetes patients. This feature addresses the specific needs of metabolic and autoimmune trials by enabling seamless device pairing, intuitive categorization of glucose readings, and real-time alerts. Such advancements aim to enhance patient adherence to study diaries, reduce overall patient burden, and ensure compliance with protocol requirements.

The company has already partnered with several leading global sponsors involved in GLP-1 and other metabolic studies, further establishing YPrime’s leadership in trials where real-time glucose monitoring is vital for success.

Previously, YPrime earned recognition as a Trailblazer in Patient Engagement by the Everest Group in 2024, confirming its focus on creating user-friendly digital tools for patients and sites. By integrating smart devices, developing intuitive eCOA interfaces, and utilizing behavioral science-informed user experiences, YPrime aims to minimize trial friction and boost participant engagement.

Operating out of Malvern, Pennsylvania, YPrime simplifies clinical trials with its eCOA, Interactive Response Technology (IRT), and eConsent solutions, combining speed, flexibility, and quality. Their platform enhances participant compliance through an intuitive app and user-friendly design, optimizing site workflows and supporting sponsors with advanced analytics for informed decision-making.

With nearly two decades of industry experience, YPrime offers solutions in over 250 languages and has established a presence in more than 100 countries. The company is dedicated to addressing clinical research challenges with certainty and reliability. For further information, visit www.yprime.com or contact [email protected].